Stockscreener 앱 받기
15.55
3.12%
-0.50
시간 외 거래:
15.34
-0.21
-1.35%
전일 마감가:
$16.05
열려 있는:
$16.27
하루 거래량:
2.95M
Relative Volume:
1.06
시가총액:
$2.34B
수익:
-
순이익/손실:
$-647.68M
주가수익비율:
-2.7425
EPS:
-5.67
순현금흐름:
$-594.49M
1주 성능:
+4.50%
1개월 성능:
+43.98%
6개월 성능:
+32.45%
1년 성능:
+12.76%
1일 변동 폭
$15.05
$16.44
1주일 범위
$14.59
$16.50
52주 변동 폭
$7.48
$18.57
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
15.55 | 2.42B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Canaccord Genuity | Buy |
| 2026-02-06 | 개시 | Goldman | Buy |
| 2026-01-21 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-11-06 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-17 | 개시 | Citigroup | Buy |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-05-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
Why Wall Street Is Growing More Cautious on Biohaven (BHVN) - Yahoo Finance
BHVNBiohaven Ltd Latest SEC Filings - Finviz
Biohaven Shares Drop 9.8% to $14.28 - Intellectia AI
Biohaven (BHVN) Insider Trading Activity 2026 - MarketBeat
Does Advancing Opakalim and BHV-1300 to Pivotal Trials Change The Bull Case For Biohaven (BHVN)? - simplywall.st
Biohaven completes enrollment in opakalim epilepsy trial - Investing.com
Biohaven completes enrollment in opakalim epilepsy trial By Investing.com - Investing.com Nigeria
Biohaven completes enrollment in focal epilepsy drug trial - StreetInsider
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator - PR Newswire
Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at BofA - Moomoo
What's Going On With Biohaven Stock Monday?Biohaven (NYSE:BHVN) - Benzinga
Biohaven (BHVN) Shares Decline Nearly 10% Amid Market Fluctuatio - GuruFocus
BHVN Downgraded by B of A Securities -- Price Target Lowered to $11 - GuruFocus
Biohaven begins phase 3 trial of BHV-1300 for Graves’ disease - Investing.com
BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - marketscreener.com
Biohaven Doses First Patient in Phase 3 Trial of BHV-1300 for Graves' Disease - marketscreener.com
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
Update: BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - Moomoo
BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target - Moomoo
BofA downgrades Biohaven stock on epilepsy drug concerns By Investing.com - Investing.com Australia
BofA Securities Downgrades Biohaven(BHVN.US) to Sell Rating, Cuts Target Price to $11 - Moomoo
BofA downgrades Biohaven stock on epilepsy drug concerns - Investing.com
Biohaven's BHV-1300 targets the root cause of Graves' disease in Phase 3 - Stock Titan
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease - Sahm
BHVN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
BHVN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
BHVN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Deutsche Bank Adjusts Biohaven Price Target to $20 From $15, Maintains Buy Rating - Moomoo
Biohaven Ltd (BHVN) Stock Price, Quote, News & History - Benzinga
Deutsche Bank Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
Biohaven Ltd. Actuals & Estimates (NYSE:BHVN) - TradingView
ZH6 Forecast — Price Target — Prediction for 2027 - TradingView
BHVN Forecast — Price Target — Prediction for 2027 - TradingView
Biohaven's Troriluzole Could Drive Potential Upside if the Company Overcomes Regulatory Hurdles, RBC Says - marketscreener.com
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Raymond James Maintains Biohaven(BHVN.US) With Buy Rating - Moomoo
Biohaven (BHVN) Is Up 22.2% After Advancing Multiple Immunology And Oncology Candidates To Pivotal Trials - Sahm
Behavioral Patterns of BHVN and Institutional Flows - Stock Traders Daily
Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials - Insider Monkey
Could Biohaven’s Expanding Pipeline Boost Russell 1000 Momentum? - Kalkine Media
Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares - simplywall.st
Biohaven Ltd (BHVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biohaven Ltd (BHVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biohaven Ltd (BHVN) Institutional Confidence - TradingKey
Biohaven Ltd (BHVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biohaven Ltd. (BHVN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
BIOHAVEN LTD (BHVN) Stock Chart - ChartMill
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations - Seeking Alpha
CCORF Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $21 - Moomoo
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오헤이븐 주식 (BHVN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Buten Matthew | Chief Financial Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
4,250 |
0 |
198,246 |
| Coric Vlad | Chief Executive Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
14,250 |
0 |
1,811,398 |
| Car Bruce | Chief Scientific Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
4,750 |
0 |
10,096 |
| Clark George C. | VP, Chief Accounting Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
2,500 |
0 |
68,095 |
| Clark George C. | VP, Chief Accounting Officer |
Nov 17 '25 |
Buy |
8.52 |
17,000 |
144,770 |
20,000 |
| Bailey Gregory | Director |
Nov 13 '25 |
Buy |
7.50 |
400,000 |
3,000,000 |
2,020,071 |
| CHILDS JOHN W | Director |
Nov 13 '25 |
Buy |
7.50 |
3,333,333 |
24,999,998 |
5,653,904 |
| Coric Vlad | Chief Executive Officer |
Nov 13 '25 |
Buy |
7.50 |
666,666 |
4,999,995 |
1,195,275 |
1.18%
2.48%
자본화:
|
볼륨(24시간):